Lloyd Klickstein - 05 Aug 2026 Form 4 Insider Report for Adicet Bio, Inc. (ACET)

Reporting relationship: Chief Medical Officer, Director
Issuer ticker: ACET
Reported as of: 05 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Aug 2026, 16:01:38 UTC
Prior SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Nick Harvey, Attorney-in-Fact

Key filing fact

Lloyd Klickstein filed Form 4 for Adicet Bio, Inc. (ACET) on 07 Aug 2026.

Key facts

This page summarizes Lloyd Klickstein's Form 4 filing for Adicet Bio, Inc. (ACET).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Aug 2026, 16:01.

Change

Previous filing in this sequence was filed on 23 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001776004 Primary reporting owner

Klickstein Lloyd

Relationship: Chief Medical Officer, Director
Address: C/O ADICET BIO, INC., 131 DARTMOUTH STREET, FLOOR 3, BOSTON
Signature: /s/ Nick Harvey, Attorney-in-Fact
Signature date: 07 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACET transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +18,300
Change %
Price: $0.000000^*
Shares after: 18,300
Date: 05 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,300
Exercise price: $9.16
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/6th of the shares subject to this option shall vest and become exercisable on each of the next six (6) monthly anniversaries of August 5, 2026, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting dates.